MENU

Hepatitis D Virus

HDV is an RNA virus that infects hepatocytes and depends on a co-existing HBV infection to produce the envelope particle which holds its genome.


HDV can be acquired at the same time or subsequent to infection with HBV, and is believed to infect between 15 and 20 million people worldwide. Chronic HDV infection results in more severe liver disease as compared to HBV infection alone, with higher risks of cirrhosis and hepatocellular carcinoma. Many chronic HDV patients progress to end-stage liver disease, where liver transplant is the only available treatment.

show more

ALN-HDV for the Treatment of HDV Infection

ALN-HDV, an investigational RNAi therapeutic targeting the HDV genome, is in development for the treatment of HDV infection. We plan to advance ALN-HDV as an ESC-GalNAc-siRNA conjugate combination with ALN-HBV targeting both the HBV and HDV genomes.

Chronic Liver Infection
PD-L1 is a cell surface protein that is believed to play a major role in suppressing the immune system in cancer and infection.

HBV and HCV infection of hepatocytes is known to lead to increased PD-L1 expression which could subdue the immune response against the virus. Further, monoclonal antibodies targeting PD-L1 and its T-cell ligand PD-1 have shown anti-viral effects in pre-clinical and early clinical studies, but are also associated with systemic toxicities.

Less Content
show more

ALN-PDL for the Treatment of Chronic Liver Infection

In the hepatic infectious disease area, we are also developing ALN-PDL, an investigational RNAi therapeutic targeting PD-L1 in development for the treatment of chronic liver infections. ALN-PDL is aimed at knocking down liver-expressed PD-L1 to reactivate an immune response against liver viral infection without the systemic toxicities observed with monoclonal antibody therapy. In pre-clinical studies published previously by Alnylam and collaborators, an siRNA targeting PD-L1 was shown to increase the endogenous immune response and viral clearance in a mouse model of liver adenovirus infection. We plan to advance ALN-PDL as an ESC-GalNAc-siRNA conjugate.
Less Content

Alnylam R&D Day 2014 Webcast and Presentations

Alnylam R&D Day 2014 Webcast and Presentations

On December 12, we hosted an R&D Day in New York City. Alnylam management and key opinion leaders discussed the latest progress as well as plans for the future development of our RNAi therapeutics pipeline. At this event, we announced our pipeline growth strategy for development and commercialization of RNAi therapeutics across three Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-metabolic Disease, and Hepatic Infectious Disease.



Read More